These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19340528)

  • 1. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders.
    Ueda K; Nannya Y; Kumano K; Hangaishi A; Takahashi T; Imai Y; Kurokawa M
    Int J Hematol; 2009 Jun; 89(5):592-9. PubMed ID: 19340528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole concentrations and outcome of invasive fungal infections.
    Miyakis S; van Hal SJ; Ray J; Marriott D
    Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
    Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
    Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
    Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
    Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.
    Troke PF; Hockey HP; Hope WW
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4782-8. PubMed ID: 21768513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.
    Chu HY; Jain R; Xie H; Pottinger P; Fredricks DN
    BMC Infect Dis; 2013 Feb; 13():105. PubMed ID: 23442261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation.
    Trifilio SM; Yarnold PR; Scheetz MH; Pi J; Pennick G; Mehta J
    Antimicrob Agents Chemother; 2009 May; 53(5):1793-6. PubMed ID: 19223632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
    Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
    Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
    Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
    Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Outcome analysis of caspofungin in combination with voriconazole for treatment of 12 hematologic malignancies cases with invasive fungal infection].
    Sun HL; Zhou X; Shen YF
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):558-9. PubMed ID: 22338183
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.
    Hoenigl M; Duettmann W; Raggam RB; Seeber K; Troppan K; Fruhwald S; Prueller F; Wagner J; Valentin T; Zollner-Schwetz I; Wölfler A; Krause R
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3262-7. PubMed ID: 23629724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
    Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
    Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
    Trifilio S; Ortiz R; Pennick G; Verma A; Pi J; Stosor V; Zembower T; Mehta J
    Bone Marrow Transplant; 2005 Mar; 35(5):509-13. PubMed ID: 15654347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.
    Mohammedi I; Piens MA; Padoin C; Robert D
    Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):358-60. PubMed ID: 15875225
    [No Abstract]   [Full Text] [Related]  

  • 17. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?
    Cherif H; Kalin M; Björkholm M
    Eur J Haematol; 2006 Oct; 77(4):288-92. PubMed ID: 16856930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.
    Vehreschild JJ; Böhme A; Reichert D; Kiehl MG; Arenz D; Pankraz K; Kochanek M; Ullmann AJ; Cornely OA
    Int J Hematol; 2008 Mar; 87(2):126-131. PubMed ID: 18288564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
    Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
    Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
    Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
    J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.